{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:08:54Z","timestamp":1791590934689,"version":"4.3.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012996","name":"University of Cyprus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010684","name":"Horizon 2020 Spreading Excellence and Widening Participation","doi-asserted-by":"publisher","award":["857122"],"award-info":[{"award-number":["857122"]}],"id":[{"id":"10.13039\/100010684","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001810","name":"Research and Innovation Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018877","name":"Research and Innovation Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009268","name":"Alport Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.kint.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:10:33Z","timestamp":1749237033000},"page":"609-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Chemical chaperone 4-phenylbutyrate treatment alleviates the kidney phenotype in a mouse model of Alport syndrome with a pathogenic variant in Col4a3"],"prefix":"10.1016","volume":"108","author":[{"given":"Pavlos","family":"Ioannou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoforos","family":"Odiatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Hadjisavva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Antoniadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrtani","family":"Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Malatras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Papagregoriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antrea","family":"Aristotelous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paris","family":"Skourides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Samiotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Hora\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica Gale\u0161i\u0107","family":"Ljubanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stylianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantinos","family":"Deltas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.05.016_bib1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"Hereditary familial congenital haemorrhagic nephritis","volume":"1","author":"Alport","year":"1927","journal-title":"Br Med J"},{"key":"10.1016\/j.kint.2025.05.016_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/ng0994-77","article-title":"Identification of mutations in the \u03b13(IV) and \u03b14(IV) collagen genes in autosomal recessive Alport syndrome","volume":"8","author":"Mochizuki","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2025.05.016_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1399-0004.2011.01647.x","article-title":"X-linked Alport syndrome in Hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5","volume":"81","author":"Demosthenous","year":"2012","journal-title":"Clin Genet"},{"key":"10.1016\/j.kint.2025.05.016_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1681\/ASN.V12197","article-title":"Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome","volume":"12","author":"Heidet","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","article-title":"X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \"European Community Alport Syndrome Concerted Action\" study","volume":"14","author":"Jais","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib6","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1093\/ndt\/gft253","article-title":"Molecular genetics of familial hematuric diseases","volume":"28","author":"Deltas","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.05.016_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000435789","article-title":"Carriers of autosomal recessive Alport syndrome with thin basement membrane nephropathy presenting as focal segmental glomerulosclerosis in later life","volume":"130","author":"Deltas","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2025.05.016_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/cge.13077","article-title":"Frequent COL4 mutations in familial microhematuria accompanied by later-onset Alport nephropathy due to focal segmental glomerulosclerosis","volume":"92","author":"Papazachariou","year":"2017","journal-title":"Clin Genet"},{"key":"10.1016\/j.kint.2025.05.016_bib9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1681\/ASN.2020071065","article-title":"Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome","volume":"32","author":"Gibson","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.2012121217","article-title":"Evidence for activation of the unfolded protein response in collagen IV nephropathies","volume":"25","author":"Pieri","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2020.100053","article-title":"A glycine substitution in the collagenous domain of Col4a3 in mice recapitulates late onset Alport syndrome","volume":"9","author":"Odiatis","year":"2021","journal-title":"Matrix Biol Plus"},{"issue":"suppl 4","key":"10.1016\/j.kint.2025.05.016_bib12","doi-asserted-by":"crossref","first-page":"iv124","DOI":"10.1093\/ndt\/gfu028","article-title":"Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies","volume":"29","author":"Gross","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.05.016_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.phrs.2016.03.017","article-title":"RAAS inhibition and the course of Alport syndrome","volume":"107","author":"Savva","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.kint.2025.05.016_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4161\/pri.28938","article-title":"The therapeutic potential of chemical chaperones in protein folding diseases","volume":"8","author":"Cortez","year":"2014","journal-title":"Prion"},{"key":"10.1016\/j.kint.2025.05.016_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-7-32","article-title":"Suggested guidelines for the diagnosis and management of urea cycle disorders","volume":"7","author":"H\u00e4berle","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2025.05.016_bib16","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.2174\/092986711798347315","article-title":"Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease","volume":"18","author":"Cuadrado-Tejedor","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib17","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.2002.0639","article-title":"Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate","volume":"6","author":"Zeitlin","year":"2002","journal-title":"Mol Ther"},{"key":"10.1016\/j.kint.2025.05.016_bib19","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib20","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/01.ASN.0000129826.28932.FD","article-title":"Defective trafficking of nephrin missense mutants rescued by a chemical chaperone","volume":"15","author":"Liu","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.taap.2010.04.005","article-title":"Effects of 4-phenylbutyric acid on the process and development of diabetic nephropathy induced in rats by streptozotocin: regulation of endoplasmic reticulum stress-oxidative activation","volume":"246","author":"Luo","year":"2010","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.kint.2025.05.016_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/srep41572","article-title":"Endoplasmic reticulum stress inhibition attenuates hypertensive chronic kidney disease through reduction in proteinuria","volume":"7","author":"Mohammed-Ali","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2025.05.016_bib23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.1128294","article-title":"Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes","volume":"313","author":"Ozcan","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.kint.2025.05.016_bib24","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.114.013395","article-title":"Molecular and genetic analyses of collagen type IV mutant mouse models of spontaneous intracerebral hemorrhage identify mechanisms for stroke prevention","volume":"131","author":"Jeanne","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2025.05.016_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/hmg\/ddt418","article-title":"Chemical chaperone treatment reduces intracellular accumulation of mutant collagen IV and ameliorates the cellular phenotype of a COL4A2 mutation that causes haemorrhagic stroke","volume":"23","author":"Murray","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2025.05.016_bib26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ekir.2017.03.004","article-title":"The chemical chaperone, PBA, reduces ER stress and autophagy and increases collagen IV alpha5 expression in cultured fibroblasts from men with X-linked Alport syndrome and missense mutations","volume":"2","author":"Wang","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.05.016_bib27","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.3390\/cells8121471","article-title":"Tauroursodeoxycholate\u2014bile acid with chaperoning activity: molecular and cellular effects and therapeutic perspectives","volume":"8","author":"Kusaczuk","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.kint.2025.05.016_bib28","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1681\/ASN.2012121149","article-title":"Laminin \u03b22 gene missense mutation produces endoplasmic reticulum stress in podocytes","volume":"24","author":"Chen","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.kint.2024.04.015","article-title":"Tauroursodeoxycholic acid ameliorates renal injury induced by COL4A3 mutation","volume":"106","author":"Yu","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.05.016_bib30","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"177","author":"Percie du Sert","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kint.2025.05.016_bib31","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1073\/pnas.1031632100","article-title":"Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats","volume":"100","author":"Rodrigues","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2025.05.016_bib32","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1471-4159.2005.03077.x","article-title":"Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice","volume":"93","author":"Ryu","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.kint.2025.05.016_bib33","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/hep.28716","article-title":"Hypothalamic kappa opioid receptor mediates both diet-induced and melanin concentrating hormone-induced liver damage through inflammation and endoplasmic reticulum stress","volume":"64","author":"Imbernon","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2025.05.016_bib34","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.2741\/3389","article-title":"TGF-beta signal transduction in chronic kidney disease","volume":"14","author":"Schnaper","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.kint.2025.05.016_bib35","first-page":"855","article-title":"Significance of alpha-SMA in myofibroblasts emerging in renal tubulointerstitial fibrosis","volume":"26","author":"Ina","year":"2011","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.kint.2025.05.016_bib36","first-page":"308","article-title":"Myofibroblasts and the progression of experimental glomerulonephritis","volume":"3","author":"Zhang","year":"1995","journal-title":"Exp Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/gte.2007.0110","article-title":"COL4A3 founder mutations in Greek-Cypriot families with thin basement membrane nephropathy and focal segmental glomerulosclerosis dating from around 18th century","volume":"12","author":"Voskarides","year":"2008","journal-title":"Genet Test"},{"key":"10.1016\/j.kint.2025.05.016_bib38","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1101\/gad.10.23.2981","article-title":"Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome","volume":"10","author":"Cosgrove","year":"1996","journal-title":"Genes Dev"},{"key":"10.1016\/j.kint.2025.05.016_bib39","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033985","article-title":"The proteasome and its network: engineering for adaptability","volume":"12","author":"Finley","year":"2020","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.kint.2025.05.016_bib40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nature07195","article-title":"Misfolded proteins partition between two distinct quality control compartments","volume":"454","author":"Kaganovich","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.kint.2025.05.016_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-biodatasci-121721-095858","article-title":"Cotranslational mechanisms of protein biogenesis and complex assembly in eukaryotes","volume":"5","author":"Morales-Polanco","year":"2022","journal-title":"Annu Rev Biomed Data Sci"},{"key":"10.1016\/j.kint.2025.05.016_bib42","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.014709","article-title":"4-Phenylbutyric acid enhances the mineralization of osteogenesis imperfecta iPSC-derived osteoblasts","volume":"296","author":"Takeyari","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib43","first-page":"638","article-title":"Correlation between mRNA expression level of the mutant COL4A5 gene and phenotypes of XLAS females","volume":"232","author":"Wang","year":"2007","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.kint.2025.05.016_bib44","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1111\/j.1523-1755.2005.00668.x","article-title":"Regulation of collagen type IV genes is organ-specific: evidence from a canine model of Alport syndrome","volume":"68","author":"Zheng","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.05.016_bib45","doi-asserted-by":"crossref","first-page":"27392","DOI":"10.1074\/jbc.274.39.27392","article-title":"Proteasomal degradation of unassembled mutant type I collagen pro-alpha1(I) chains","volume":"274","author":"Fitzgerald","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib46","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.1074\/jbc.270.15.8642","article-title":"Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro alpha 1 (I) chain carboxyl-terminal propeptide which impair subunit assembly","volume":"270","author":"Lamande","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib47","doi-asserted-by":"crossref","first-page":"C483","DOI":"10.1152\/ajpcell.00776.2024","article-title":"Identification of polycystin 2 missense mutants targeted for endoplasmic reticulum-associated degradation","volume":"328","author":"Guerriero","year":"2025","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.kint.2025.05.016_bib48","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/CM9.0000000000000294","article-title":"Endoplasmic reticulum stress and proteasome pathway involvement in human podocyte injury with a truncated COL4A3 mutation","volume":"132","author":"Zhang","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.kint.2025.05.016_bib49","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1074\/jbc.RA120.014071","article-title":"Elucidation of proteostasis defects caused by osteogenesis imperfecta mutations in the collagen-alpha2(I) C-propeptide domain","volume":"295","author":"Doan","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.kint.2025.05.016_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000445171","article-title":"Non-transgenic mouse models of kidney disease","volume":"133","author":"Rabe","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2025.05.016_bib51","doi-asserted-by":"crossref","first-page":"F674","DOI":"10.1152\/ajprenal.00196.2020","article-title":"C57BL\/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury","volume":"319","author":"Sears","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2025.05.016_bib52","doi-asserted-by":"crossref","first-page":"F1125","DOI":"10.1152\/ajprenal.00219.2004","article-title":"Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice","volume":"288","author":"Yang","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2025.05.016_bib53","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3390\/genes13101893","article-title":"A comparative presentation of mouse models that recapitulate most features of Alport syndrome","volume":"13","author":"Nikolaou","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.kint.2025.05.016_bib54","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/03008207.2022.2036735","article-title":"Collagen misfolding mutations: the contribution of the unfolded protein response to the molecular pathology","volume":"63","author":"Bateman","year":"2022","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.kint.2025.05.016_bib55","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1016\/j.bmcl.2013.08.001","article-title":"4-Phenylbutyric acid protects against neuronal cell death by primarily acting as a chemical chaperone rather than histone deacetylase inhibitor","volume":"23","author":"Mimori","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.kint.2025.05.016_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7453\/gahmj.2014.017","article-title":"The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases","volume":"3","author":"Vang","year":"2014","journal-title":"Glob Adv Health Med"},{"key":"10.1016\/j.kint.2025.05.016_bib57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.metabol.2010.07.021","article-title":"Attenuation of diabetic nephropathy in diabetes rats induced by streptozotocin by regulating the endoplasmic reticulum stress inflammatory response","volume":"60","author":"Qi","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.kint.2025.05.016_bib58","doi-asserted-by":"crossref","first-page":"F230","DOI":"10.1152\/ajprenal.00119.2016","article-title":"Endoplasmic reticulum stress inhibition limits the progression of chronic kidney disease in the Dahl salt-sensitive rat","volume":"312","author":"Yum","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2025.05.016_bib59","doi-asserted-by":"crossref","first-page":"22116","DOI":"10.18632\/oncotarget.7904","article-title":"Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.kint.2025.05.016_bib60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/jcp.25836","article-title":"4PBA strongly attenuates endoplasmic reticulum stress, fibrosis, and mitochondrial apoptosis markers in cyclosporine treated human gingival fibroblasts","volume":"233","author":"Ranga Rao","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.kint.2025.05.016_bib61","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cbi.2014.10.032","article-title":"Attenuation of ER stress prevents post-infarction-induced cardiac rupture and remodeling by modulating both cardiac apoptosis and fibrosis","volume":"225","author":"Luo","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.kint.2025.05.016_bib62","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/pr.117.015370","article-title":"A practical review of proteasome pharmacology","volume":"71","author":"Thibaudeau","year":"2019","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.kint.2025.05.016_bib63","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1172\/JCI549","article-title":"Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency","volume":"101","author":"Novoradovskaya","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.kint.2025.05.016_bib64","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/hmg\/ddy369","article-title":"4-Sodium phenyl butyric acid has both efficacy and counter-indicative effects in the treatment of Col4a1 disease","volume":"28","author":"Jones","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2025.05.016_bib65","doi-asserted-by":"crossref","first-page":"12461","DOI":"10.1073\/pnas.1204991109","article-title":"Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1","volume":"109","author":"Manka","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2025.05.016_bib66","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/hmg\/ddt560","article-title":"Allelic heterogeneity contributes to variability in ocular dysgenesis, myopathy and brain malformations caused by Col4a1 and Col4a2 mutations","volume":"23","author":"Kuo","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.kint.2025.05.016_bib67","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.chembiol.2018.02.003","article-title":"A split-luciferase-based trimer formation assay as a high-throughput screening platform for therapeutics in Alport syndrome","volume":"25","author":"Omachi","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.kint.2025.05.016_bib68","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1681\/ASN.2005101044","article-title":"Chronic renal failure and shortened lifespan in COL4A3+\/- mice: an animal model for thin basement membrane nephropathy","volume":"17","author":"Beirowski","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.05.016_bib69","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ekir.2022.06.001","article-title":"Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities","volume":"7","author":"Savige","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.05.016_bib70","article-title":"Genotype-phenotype correlations for pathogenic COL4A3-COL4A5 variants in X-linked, autosomal recessive, and autosomal dominant Alport syndrome","volume":"9","author":"Savige","year":"2022","journal-title":"Front Med (Lausanne)"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825004260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253825004260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:42:20Z","timestamp":1762231340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253825004260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0085253825004260"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.05.016","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical chaperone 4-phenylbutyrate treatment alleviates the kidney phenotype in a mouse model of Alport syndrome with a pathogenic variant in Col4a3","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.07.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}